Hologic stock: Company reports Breast Cancer Index study findings
Published on 09/29/2026 at 22:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hologic reported new findings from a Breast Cancer Index registry study on September 24, 2026. The company said test results led physicians to change their extended endocrine therapy recommendations for 42% of patients in the final analysis of the study.
Hologic said the registry study included nearly 3,000 patients with early-stage, hormone receptor-positive breast cancer. In two-thirds of the cases in which recommendations changed, physicians recommended against extending treatment. The company also reported that 83% of patients in the analysis reported side effects.
Updated report option
Hologic said physicians can access an updated version of the Breast Cancer Index report as of July 2026. The updated option provides additional context on 10-year recurrence risk at the time of diagnosis, according to the company.
